PEB Stock Overview
Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, Australia, and Singapore.
Pacific Edge Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||NZ$0.52|
|52 Week High||NZ$1.59|
|52 Week Low||NZ$0.40|
|1 Month Change||-26.76%|
|3 Month Change||-36.59%|
|1 Year Change||-57.72%|
|3 Year Change||131.11%|
|5 Year Change||9.47%|
|Change since IPO||197.15%|
Recent News & Updates
Pacific Edge (NZSE:PEB) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
|PEB||NZ Biotechs||NZ Market|
Return vs Industry: PEB underperformed the NZ Biotechs industry which returned -1.6% over the past year.
Return vs Market: PEB underperformed the NZ Market which returned -11.3% over the past year.
|PEB Average Weekly Movement||14.2%|
|Biotechs Industry Average Movement||11.7%|
|Market Average Movement||4.4%|
|10% most volatile stocks in NZ Market||8.3%|
|10% least volatile stocks in NZ Market||3.0%|
Stable Share Price: PEB is more volatile than 90% of NZ stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: PEB's weekly volatility has increased from 8% to 14% over the past year.
About the Company
Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, Australia, and Singapore. It operates in two segments, Commercial and Research. The company offers Cxbladder, a genomic urine tests for the detection and management of bladder cancer.
Pacific Edge Fundamentals Summary
|PEB fundamental statistics|
Is PEB overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PEB income statement (TTM)|
|Cost of Revenue||NZ$6.50m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Nov 26, 2022
|Earnings per share (EPS)||-0.024|
|Net Profit Margin||-150.64%|
How did PEB perform over the long term?See historical performance and comparison
Is PEB undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PEB?
Other financial metrics that can be useful for relative valuation.
|What is PEB's n/a Ratio?|
Price to Sales Ratio vs Peers
How does PEB's PS Ratio compare to its peers?
|PEB PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
AFT AFT Pharmaceuticals
4728 Sunmax Biotechnology
AVEO AVEO Pharmaceuticals
PEB Pacific Edge
Price-To-Sales vs Peers: PEB is expensive based on its Price-To-Sales Ratio (32.1x) compared to the peer average (4.9x).
Price to Earnings Ratio vs Industry
How does PEB's PE Ratio compare vs other companies in the Oceanian Biotechs Industry?
Price-To-Sales vs Industry: PEB is expensive based on its Price-To-Sales Ratio (32.1x) compared to the Oceanic Biotechs industry average (20.1x)
Price to Sales Ratio vs Fair Ratio
What is PEB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||32.1x|
|Fair PS Ratio||20.7x|
Price-To-Sales vs Fair Ratio: PEB is expensive based on its Price-To-Sales Ratio (32.1x) compared to the estimated Fair Price-To-Sales Ratio (20.7x).
Share Price vs Fair Value
What is the Fair Price of PEB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: PEB (NZ$0.52) is trading above our estimate of fair value (NZ$0.11)
Significantly Below Fair Value: PEB is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
How is Pacific Edge forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PEB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PEB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PEB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PEB's revenue (45.7% per year) is forecast to grow faster than the NZ market (5.8% per year).
High Growth Revenue: PEB's revenue (45.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PEB is forecast to be unprofitable in 3 years.
Discover growth companies
How has Pacific Edge performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PEB is currently unprofitable.
Growing Profit Margin: PEB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PEB is unprofitable, but has reduced losses over the past 5 years at a rate of 5.6% per year.
Accelerating Growth: Unable to compare PEB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PEB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: PEB has a negative Return on Equity (-18.26%), as it is currently unprofitable.
Discover strong past performing companies
How is Pacific Edge's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: PEB's short term assets (NZ$111.6M) exceed its short term liabilities (NZ$6.1M).
Long Term Liabilities: PEB's short term assets (NZ$111.6M) exceed its long term liabilities (NZ$851.0K).
Debt to Equity History and Analysis
Debt Level: PEB is debt free.
Reducing Debt: PEB has no debt compared to 5 years ago when its debt to equity ratio was 0.01%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PEB has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if PEB has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
What is Pacific Edge current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PEB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PEB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PEB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PEB's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as PEB has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Peter Meintjes served as a Chief Commercial Officer at Transplant Genomics, Inc., since April 2020. he serves as CEO at Pacific Edge Limited since January 17, 2022. He was responsible for leding the co...
Experienced Management: PEB's management team is considered experienced (2.6 years average tenure).
Experienced Board: PEB's board of directors are considered experienced (6.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.1%.
Pacific Edge Limited's employee growth, exchange listings and data sources
- Name: Pacific Edge Limited
- Ticker: PEB
- Exchange: NZSE
- Founded: 2001
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: NZ$413.192m
- Shares outstanding: 810.18m
- Website: https://www.pacificedgedx.com
Number of Employees
- Pacific Edge Limited
- Centre for Innovation
- 87 St David Street
- New Zealand
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/09 00:00|
|End of Day Share Price||2022/08/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.